Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies.
De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, Hercogová J, Hong CH, Katoh N, Pink AE, Richard MA, Shumack S, Silvestre JF, Weidinger S. De Bruin-Weller M, et al. Among authors: pink ae. Acta Derm Venereol. 2021 Feb 17;101(2):adv00402. doi: 10.2340/00015555-3751. Acta Derm Venereol. 2021. PMID: 33491094 Free PMC article.
The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada.
de Bruin-Weller M, Gadkari A, Auziere S, Simpson EL, Puig L, Barbarot S, Girolomoni G, Papp K, Pink AE, Saba G, Werfel T, Eckert L. de Bruin-Weller M, et al. Among authors: pink ae. J Eur Acad Dermatol Venereol. 2020 May;34(5):1026-1036. doi: 10.1111/jdv.16003. Epub 2020 Jan 14. J Eur Acad Dermatol Venereol. 2020. PMID: 31587373 Free PMC article.
Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.
Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, Hijnen D, Jensen TN, Bang B, Olsen CK, Kurbasic A, Weidinger S; ECZTRA 3 study investigators. Silverberg JI, et al. Among authors: pink ae. Br J Dermatol. 2021 Mar;184(3):450-463. doi: 10.1111/bjd.19573. Epub 2021 Feb 22. Br J Dermatol. 2021. PMID: 33000503 Free PMC article. Clinical Trial.
Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study.
Bruin-Weller M, Pink AE, Patrizi A, Gimenez-Arnau AM, Agner T, Roquet-Gravy PP, Ferrucci SM, Arenberger P, Svensson A, Schuttelaar MLA, Nosbaum A, Jayawardena S, Rizova E, Ardeleanu M, Eckert L, Ozturk ZE. Bruin-Weller M, et al. Among authors: pink ae. J Dermatolog Treat. 2021 Mar;32(2):164-173. doi: 10.1080/09546634.2020.1866741. Epub 2021 Jan 18. J Dermatolog Treat. 2021. PMID: 33461356
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE, Kataoka Y, Chu CY, DiBonaventura M, Rojo R, Antinew J, Ionita I, Sinclair R, Forman S, Zdybski J, Biswas P, Malhotra B, Zhang F, Valdez H; JADE COMPARE Investigators. Bieber T, et al. Among authors: pink ae. N Engl J Med. 2021 Mar 25;384(12):1101-1112. doi: 10.1056/NEJMoa2019380. N Engl J Med. 2021. PMID: 33761207 Clinical Trial.
Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7).
Gutermuth J, Pink AE, Worm M, Soldbro L, Bjerregård Øland C, Weidinger S. Gutermuth J, et al. Among authors: pink ae. Br J Dermatol. 2022 Mar;186(3):440-452. doi: 10.1111/bjd.20832. Epub 2021 Dec 22. Br J Dermatol. 2022. PMID: 34698371 Clinical Trial.
Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD).
de Bruin-Weller M, Pink AE, Ferrucci SM, Patrizi A, Svensson A, Schuttelaar MLA, Tauber M, Ardeleanu M, Jayawardena S, Daoud M. de Bruin-Weller M, et al. Among authors: pink ae. J Dermatolog Treat. 2022 Aug;33(5):2565-2570. doi: 10.1080/09546634.2022.2038361. Epub 2022 Mar 8. J Dermatolog Treat. 2022. PMID: 35255779
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
Silverberg JI, Adam DN, Zirwas M, Kalia S, Gutermuth J, Pinter A, Pink AE, Chiricozzi A, Barbarot S, Mark T, Tindberg AM, Weidinger S. Silverberg JI, et al. Among authors: pink ae. Am J Clin Dermatol. 2022 Jul;23(4):547-559. doi: 10.1007/s40257-022-00702-2. Epub 2022 Jul 20. Am J Clin Dermatol. 2022. PMID: 35857179 Free PMC article. Clinical Trial.
Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis.
Reich K, Lio PA, Bissonnette R, Alexis AF, Lebwohl MG, Pink AE, Kabashima K, Boguniewicz M, Nowicki RJ, Valdez H, Zhang F, DiBonaventura M, Cameron MC, Clibborn C. Reich K, et al. Among authors: pink ae. J Allergy Clin Immunol Pract. 2022 Dec;10(12):3228-3237.e2. doi: 10.1016/j.jaip.2022.08.042. Epub 2022 Sep 13. J Allergy Clin Immunol Pract. 2022. PMID: 36108923 Free article. Clinical Trial.
75 results